Navigation Links
CEL-SCI Takes Delivery of New Manufacturing Facility
Date:10/9/2008

VIENNA, Va., Oct. 9 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE: CVM) announced today that it has taken delivery of the new manufacturing facility for its lead drug Multikine(R). This dedicated facility, located in the Baltimore area, will produce the Multikine that will be used for CEL-SCI's pivotal Phase III clinical trial for first-line therapy of previously untreated head and neck cancer patients, and subsequently for sale following approval of the drug. The facility, which cost about $22 million to build, is state of the art and will soon be commercial ready. As it stands today, the facility can produce about $600 million worth of drug per year. Within one year it can be built out to product almost $2 billion worth of drug per year.

Geert Kersten, CEL-SCI's Chief Executive Officer said, "Multikine started with the idea that activating the immune system to fight cancer could be beneficial and successful, as long as you could activate the immune system before it was weakened by surgery, radiation and chemotherapy. Our clinical studies showed significant benefit to the cancer patients treated with Multikine. We are now in the home stretch. Having our own Multikine dedicated manufacturing facility gives us control and eliminates a great deal of risk from our product development. Our next step is to completely validate the facility and to bring it on line for manufacturing."

CEL-SCI is developing Multikine for approval as a first line indication in head and neck cancer. To that end, the Company's upcoming Phase III clinical trial is an 800 patient clinical study designed to demonstrate that administration of its cancer drug Multikine to head and neck cancer patients before they receive any conventional cancer treatmen
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
6. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
7. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
8. Ground-Breaking Conference Takes on Abortion
9. White Paper Advises Pharma Manufacturers on How to Select an Aseptic Fill/Finish Contractor, Avoid the Most Common Mistakes
10. Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic
11. Tepper School Team Takes Top Honors at Global Moot Corp(R) Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... (PRWEB) July 30, 2014 ... and collaboration company, is proud to announce the ... management positions in their Boston, Charleston and Atlanta ... to the increased demand for hosted solutions, collaboration ... efficiency and reduce cost. , SoundConnect was founded ...
(Date:7/29/2014)... Bellingham, WA (PRWEB) July 29, 2014 ... manipulation of the brain that are driving a revolution ... a new peer-reviewed journal published by SPIE, ... The first issue coincides with the launch of the ... section features articles that lay out a vision for ...
(Date:7/29/2014)... Quantum Cheshire Cat: Can a particle be separated from ... Nature Communications , published the results of the first ... field, conducted by Chapman University in Orange, CA, and ... seen a cat without a grin," thought Alice in ... most curious thing I ever saw in my life!" ...
(Date:7/29/2014)... July 29, 2014  The Society for Clinical ... updated program for the 9 th annual ... in Amelia Island , Florida.  The focus ... remains unchanged, however, the topics and format will ... opportunity among all stakeholders with a continued focus ...
Breaking Biology Technology:SoundConnect Organization and Culture is Evolving 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3
... (Nasdaq: ITMN ) today announced additions to ... of Esbriet™ (pirfenidone) in Europe.  InterMune,s Marketing Authorization Application ... is now awaiting ratification by the European Commission. ... of InterMune, said, "We are very pleased by the ...
... Dec. 17, 2010 RIFM, through its sponsorship of ... announce the resulting paper, Integrating population modeling into ... al , published in Integrated Environmental Assessment and Management ... of this journal according to Wiley-Blackwell and SETAC, publishers, ...
... from the Institut Catal de Nanotecnologia (ICN), in Barcelona, has ... electric currents, a key step in developing the spin computers ... 17 issue of the journal Science. The authors are Marius ... is leader of the Physics and Engineering of Nanodevices Group ...
Cached Biology Technology:InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 2InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 3InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 4InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 5InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 6RIFM Co-Authors Environmental Article - Among Top 5 Most Downloaded 2A 'spin ratchet': A new electronic structure for generating spin current 2
(Date:7/30/2014)... , July 30, 2014 NexID ... and liveness detection solutions for the biometric authentication ... industry consortium revolutionizing online authentication with standards for ... Cornett , "The decision to join FIDO Alliance ... authentication pervasive in use. We believe the FIDO ...
(Date:7/30/2014)... across-the-board increase in Impact Factors for its molecular ... Reports (Thomson Reuters, 2014) show that Clinical ... in Biochemistry , Biochemical Society Transactions ... in their Impact Factors. The journals are owned ... Press Limited. , 2014 Impact Factors (2013 Impact ...
(Date:7/30/2014)... decisions about what they eat, the Food and Drug ... the Nutrition Facts label found on nearly every food ... & Engineering News (C&EN), the weekly news magazine ... and the fight that has ensued. , Britt ... while the Nutrition Facts label has remained largely the ...
Breaking Biology News(10 mins):NexID Biometrics Joins the FIDO Alliance 2Across-the-board Impact Factor increases for Portland Press Limited 2
... Cornell University evolutionary biology research shows how plants at ... that influence ecosystem dynamics as well. ( Science, ... most organisms is dictated by their evolutionary history," said ... (EEB), the study,s senior author. In food webs, ...
... This release is available in Spanish . ... Agricultural Research and Development (Neiker-Tecnalia) has questioned the generally held ... exposure to natural light and states that the most determining ... Institute,s Department of Agricultural Production and Protection and opens up ...
... A protein discovered in fruit fly eyes has brought ... heart and other organs automatically "right size" themselves, a piece ... The protein, named Kibra, is linked to a relay ... by coordinating control of cell proliferation and death, according to ...
Cached Biology News:Move over predators: Plants can control the food chain too -- from the bottom up 2The quality of the tomato depends more on temperature than on natural light 2How does a heart know when it's big enough? 2
Mouse monoclonal [TONI-1] to Angiotensin II Type 1 Receptor (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 185 SwissProtID: P30556...
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
HSV-1 gE Envelope Protein (9H3)...
... by their capacity to self renew and ... progenitor cells, which can commit to further ... (NSCs) are capable of differentiating into multiple ... During the isolation and expansion of NSCs, ...
Biology Products: